Quantcast

Latest ImaginAb Inc. Stories

2014-07-28 08:29:07

LOS ANGELES, SINGAPORE, and TOKYO, July 28, 2014 /PRNewswire/ -- ImaginAb, Inc. today announced today announced that it has appointed Roger Crystal, MD as Vice President of Business Development. Dr. Crystal most recently served in the Global Business Development Product Acquisition & Licensing team at G.E. Life Sciences. "Roger's experience in developing business strategy and partnerships in the precision medicine space will be extremely valuable as we continue to partner with...

2014-06-10 16:27:01

NEW YORK and LOS ANGELES, June 10, 2014 /PRNewswire/ -- NCM USA announced today it has signed a long-term clinical zirconium isotope ((89)Zr) supply and cGMP biologics labeling agreement with ImaginAb, Inc., an innovation leader in the use of biologics for imaging with Positron Emission Tomography (PET). The NCM radiopharmaceutical manufacturing footprint specializes in "next generation" cyclotron-generated PET isotopes, including (89)Zr, and incorporates advanced automation and...

2014-06-09 08:28:48

IBA to Manufacture and Supply 89Zr-Df-IAB2M for Multi-Center Studies in the US LOS ANGELES and DULLES, Va., June 9, 2014 /PRNewswire/ -- ImaginAb, Inc. (ImaginAb) and IBA Molecular North America, Inc. (IBA Molecular) announced that IBA Molecular has been selected to provide radiochemistry manufacturing and clinical distribution of (89)Zr-Df-IAB2M, an immunoPET tracer for imaging prostate cancer, to support multi-center clinical studies in the US. IBA Molecular will manufacture...

2014-06-06 08:24:52

Initial clinical experience with 89Zr-labeled anti-PSMA minibody presented LOS ANGELES, June 6, 2014 /PRNewswire/ -- ImaginAb, Inc., in collaboration with Memorial Sloan-Kettering Cancer Center (MKSCC), will be presenting initial clinical data with an anti-PSMA recombinant antibody fragment (a "minibody") derived from the huJ591 monoclonal antibody, in patients with metastatic prostate cancer. The presentation of this initial data coincides with the Company's preparation to expand...

2014-06-03 12:36:41

ImaginAb Expands Portfolio for Immunotherapeutic Drug Development LOS ANGELES, June 3, 2014 /PRNewswire/ -- ImaginAb, Inc. and the Regents of the University of California, Los Angeles (UCLA) have executed a technology licensing agreement relating to novel immune cell-targeting agents for imaging with Positron Emission Tomography (PET). Inflammation and immune response play a fundamental role in a wide variety of diseases including cancer and autoimmune diseases. Under the agreement,...

2014-05-08 16:26:11

LOS ANGELES and SINGAPORE, May 8, 2014 /PRNewswire/ -- ImaginAb, Inc., a clinical stage biotechnology company that engineers antibodies into smaller protein formats optimized for in vivo molecular imaging, announced today the completion of a $21M Series B financing of the company, led by Mérieux Développement and syndicated with Novartis Venture Funds, Cycad Group and Nextech Invest. Dr. Christian Behrenbruch, co-founder and CEO of ImaginAb commented, "We have made excellent...

2014-02-10 08:27:34

Major new precision medicine initiative takes root in Singapore SINGAPORE and LOS ANGELES, Feb. 10, 2014 /PRNewswire/ -- ImaginAb, Inc. today announced that it has entered into a partnership with the Duke-NUS Graduate Medical School Singapore (Duke-NUS) to establish a joint corporate laboratory to develop new in vivo molecular imaging agents to study cancer biology and immune function. ImaginAb is a U.S. clinical-stage company that develops in vivo molecular imaging agents based on a...


Word of the Day
cenobite
  • One of a religious order living in a convent or in community; a monk: opposed to anchoret or hermit (one who lives in solitude).
  • A social bee.
This word comes from the Latin 'coenobium,' convent, which comes from the Greek 'koinobios,' living in community.
Related